



UNIVERSITY of MARYLAND SCHOOL OF MEDICINE

 [Update Your Profile](#)

Deanna L. Kelly, PharmD, BCPP

Academic Title:

Professor

Primary Appointment:

Psychiatry

Additional Title:

Professor of Psychiatry, Director of Treatment Research Program at MPRC, Affiliate Professor of Pharmacy Practice and Science

Email:

dlkelly@som.umaryland.edu

Location:

MPRC, Treatment Research Program

Phone (Primary):

410-402-6861

Phone (Secondary):

410-402-6860

Fax:

410-402-6880

[Download CV](#)

Education and Training

Education

- Duquesne University, Mylan School of Pharmacy (Magna Cum Laude), B.S., Pharmacy, 1995
- Duquesne University, Mylan School of Pharmacy, Pharm.D., 1996

Post Graduate Education and Training

- University of Maryland Baltimore, Psychiatric Pharmacy Practice Residency, 1996–1997

Certifications

- Board Certified in Psychiatric Pharmacy Practice, 1998–present

Biosketch

Deanna L. Kelly, Pharm.D., BCPP is Professor of Psychiatry at University of Maryland Baltimore School of Medicine and Affiliate Professor in the School of Pharmacy. She is currently Director and Chief of the Treatment Research Program at the Maryland Psychiatric Research Center (MPRC). Dr. Kelly received her Bachelor of Science and Doctorate in Pharmacy at Duquesne University in Pittsburgh, PA. She completed residency training in psychiatric pharmacy practice at the University of Maryland in 1997 and became board certified in psychiatric pharmacy practice in 1998.

Dr. Kelly has led and been involved in numerous clinical trials in schizophrenia and has been active in psychopharmacology research for the past 21 years. She has been continuously funded by NIMH, NIDA, and private foundations such as the Stanley Medical Research Institute and the Maryland Innovation Initiative for over 17 years. She has specific interest in studying new treatments, women's mental health, clozapine and immune function and inflammation.

Dr. Kelly has coauthored and authored 18 books and book chapters, published 175 peer-reviewed articles, presented over 140 posters and has given over 140 invited lectures. She has coauthored three editions of the book entitled "Pharmacologic Treatment of Schizophrenia." She also authors the Schizophrenia chapter for "Pharmacotherapy, Principles and Practice." Among many other activities she reviews for over 30 psychiatry journals and serves as a founding and current Associate Editor for Clinical Schizophrenia and Related Psychoses. Dr Kelly chairs the Junior Faculty Mentoring Committee at MPRC, and serves as Vice Chair of the State of Maryland Department of Health and Mental Hygiene Institutional Review Board.

She is the past President for the College of Psychiatric & Neurologic Pharmacists and recipient of the 2017 Maltz Prize for Innovative and Promising Schizophrenia Research from the Brain and Behavior Research Foundation

Research/Clinical Keywords

Schizophrenia research, antipsychotic medication, women, gluten, clozapine, inflammation, clinical trials.

Highlighted Publications

Kelly, DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, Keller WR, Koola MM, Feldman, SM, Russ JC, Keefe RS, Osing J, Hubzin L, August A, Walker TM, Buchanan RW. Adjunctive Minocycline in clozapine treated schizophrenia patients with persistent symptoms. *J Clin Psychopharmacol.* 2015 Aug;35(4):374–81. doi: 10.1097/JCP.0000000000000345. PMID: 26082974

Richardson CM*, Davis EA,* Vyas GR, DiPaula BA, McMahon RP, Kelly DL. Evaluation of the safety of clozapine use in patients with benign neutropenia. *J Clin Psych* 2016;77(11):e1454–e1459. PMID: 27736047.

Cihakova D, Eaton WW, Talor MV, Harkus UH, Demyanovich H, Rodriguez K, Feldman S, Kelly DL. Gliadin-related antibodies in schizophrenia. *Schizophrenia Research*, 2018;195;585-586 PMID: 28886891

Kelly DL, Freudenreich O, Sayer MA, Love RC. Addressing barriers to clozapine underutilization: a national effort. *Psychiatr Serv* 2018;69:224-227. PMID 29032704

Kelly DL, Demyanovich HK, Eaton W, Cascella N, Jackson J, Fasano A, Carpenter WT. Antigliadin antibodies (AGA IgG) related to peripheral inflammation in schizophrenia. *Brain Behav Immun* 2018;69:57-59. PMID 29074356

Kelly DL, Powell MM, Wehring HJ, Sayer MA, Kearns AM, Hackman AL, Buchanan RW, Nichols RB, Adams HA, Richardson CM, Vyas G, McMahon RP, Earl AK, Sullivan KM, Liu F, Luttrell SE, Dickerson FB, Feldman SM, Narang S, Koola MM, Buckley PF, RachBeisel JA, McEvoy JP. Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial. *J Clin Psychopharmacol*. 2018 Aug;38(4):317-326. PMID: 29912799

Kelly DL, Li X, Kilday C, Feldman S, Clark S, Liu F, Buchanan RW, Tonelli LH. Increased circulating regulatory T cells in medicated people with schizophrenia. *Psychiatry Res*. 2018 Sep 5;269:517-523. doi: 10.1016/j.psychres.2018.09.006. [Epub ahead of print] PMID: 30195746

 [Update Your Profile](#)